Weak On High Volume: Bellicum Pharmaceuticals (BLCM)

Trade-Ideas LLC identified Bellicum Pharmaceuticals (BLCM) as a weak on high relative volume candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Bellicum Pharmaceuticals

(

BLCM

) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Bellicum Pharmaceuticals as such a stock due to the following factors:

  • BLCM has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $7.4 million.
  • BLCM has traded 148,237 shares today.
  • BLCM is trading at 2.09 times the normal volume for the stock at this time of day.
  • BLCM is trading at a new low 4.16% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in BLCM with the Ticky from Trade-Ideas. See the FREE profile for BLCM NOW at Trade-Ideas

More details on BLCM:

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Currently there are 3 analysts that rate Bellicum Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Bellicum Pharmaceuticals has been 321,500 shares per day over the past 30 days. Bellicum has a market cap of $396.9 million and is part of the health care sector and drugs industry. Shares are down 26.2% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Bellicum Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 94.3% when compared to the same quarter one year ago, falling from -$7.76 million to -$15.08 million.
  • Net operating cash flow has significantly decreased to -$11.24 million or 59.95% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The share price of BELLICUM PHARMACEUTICALS INC has not done very well: it is down 24.92% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • BELLICUM PHARMACEUTICALS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, BELLICUM PHARMACEUTICALS INC continued to lose money by earning -$1.84 versus -$2.87 in the prior year. For the next year, the market is expecting a contraction of 23.9% in earnings (-$2.28 versus -$1.84).
  • The revenue fell significantly faster than the industry average of 19.6%. Since the same quarter one year prior, revenues fell by 14.0%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...